Meier Megan, Linn Becky S
Veterans Affairs Eastern Colorado Healthcare System, Aurora, USA.
University of Wyoming, Laramie, USA.
J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241260959. doi: 10.1177/23247096241260959.
Patients infected with COVID-19 can develop coinfections or acute respiratory disorder that result in ventilation. Dexmedetomidine is a common medication used to sedate ventilated patients in the intensive care unit and for nonintubated patients prior to a surgical procedure. As a highly selective alpha-2 agonist, dexmedetomidine provides sedation while reducing the need for anxiolytics or opioids. However, previous case reports suggest dexmedetomidine can induce fever in a variety of conditions. The purpose of this case report is to describe a patient who acquired a fever of 42.6°C in the setting of COVID-19 after administration of dexmedetomidine.
感染新型冠状病毒肺炎(COVID-19)的患者可能会发生合并感染或急性呼吸功能障碍,进而需要通气支持。右美托咪定是一种常用药物,用于在重症监护病房对接受通气的患者进行镇静,以及在手术前对未插管的患者进行镇静。作为一种高度选择性的α-2激动剂,右美托咪定在减少对苯二氮䓬类或阿片类药物需求的同时提供镇静作用。然而,既往病例报告提示右美托咪定在多种情况下可诱发发热。本病例报告的目的是描述一名在COVID-19背景下使用右美托咪定后出现42.6°C发热的患者。